Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 1;18(6):699-701.
doi: 10.2215/CJN.0000000000000171. Epub 2023 May 15.

Prognosis of IgA Nephropathy: A Lifetime Story

Joyita Bharati  1   2 , Kenar D Jhaveri  2
Affiliations
Editorial

Prognosis of IgA Nephropathy: A Lifetime Story

Joyita Bharati et al. Clin J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Choosing a novel aggressive approach over the conventional liberal approach in treating IgA nephropathy might avoid kidney failure in patient's expected lifetime. *In clinical trials, not approved yet. ACEi, angiotensin‐converting enzyme inhibitor; APRIL, a proliferation-inducing ligand; ARB, angiotensin receptor blocker; MMF, mycophenolate mofetil; SGLT2i, sodium‐glucose cotransporter 2 inhibitor.
See this image and copyright information in PMC

Comment on

  • Long-Term Outcomes in IgA Nephropathy.
    Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Pitcher D, et al. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13. Clin J Am Soc Nephrol. 2023. PMID: 37055195 Free PMC article.

References

    1. Barbour SJ Coppo R Zhang H et al. .. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942–952. doi:10.1001/jamainternmed.2019.0600. - DOI - PMC - PubMed
    1. Barratt J Hour B Kooienga L et al. .. POS-109 Interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy. Kidney Int Rep. 2022;7(2):S46. doi:10.1016/j.ekir.2022.01.121 - DOI
    1. Rovin BH Adler SG Barratt J et al. .. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):S1–S276. doi:10.1016/j.kint.2021.05.021 - DOI - PubMed
    1. Ibels LS, Györy AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine. 1994;73(2):79–102. doi:10.1097/00005792-199403000-00002 - DOI - PubMed
    1. Maixnerova D Bauerova L Skibova J et al. .. The retrospective analysis of 343 Czech patients with IgA nephropathy–one centre experience. Nephrol Dial Transplant. 2012;27(4):1492–1498. doi:10.1093/ndt/gfr482 - DOI - PubMed

Substances